Companies
Companies
Mogu Srl Secures €11m to Revolutionize Mycelium Technology
📢 Italian mycelium specialist Mogu Srl raises €11m to scale technology, accelerate industrial scaling, and boost R&D efforts. 💰🍄
Game-Changing Respiratory Breakthrough: GSK’s $14bn Aiolos Bio Acquisition!
📢 GSK breathes new life into its respiratory pipeline with $1.4bn Aiolos Bio acquisition, reinforcing commitment to patients worldwide. 😷💊🌍
Vertex Launches Casgevy: Revolutionary Gene Editing for Genetic Diseases
📚 Vertex Pharmaceuticals launches Casgevy, targeting gene editing therapies for sickle cell disease and beta thalassemia. 💰 This move strengthens Vertex's position in genetic diseases and aims for significant impact in the field.
Million-Dollar Boost to Fight Drug-Resistant Infections
💰 The Novo Nordisk Foundation invests $25m in partnership with CARB-X to combat drug-resistant infections and support innovation.
Enzene Biosciences Sets Up US Manufacturing Site to Meet Rising Biotech Demand
📢 Enzene Biosciences plans to set up its inaugural US manufacturing site to meet the rising demand for biotech products. 😷🏭
J&J Invests $2bn in Game-Changing Cancer Treatments
🔍 Johnson & Johnson acquires Ambrx for $2bn to boost its ADC pipeline and advance innovative cancer treatments. 💼🌐💉
Merck Acquiring Harpoon for $680M: Revolutionizing Cancer Treatment!
📰 Merck buys Harpoon Therapeutics for $680m, boosting its cancer treatment capabilities. 💊💉 Exciting move in immuno-oncology! 🌟👨🔬🚀
Revolutionary RSV Treatment Approved in China!
📝 AZ's Beyfortus authorized as first RSV treatment in China! 💊🇨🇳 Significant breakthrough in biotech industry. 👏😃
Novartis Acquires Immunology Specialist in $425M Deal
📰 Novartis AG to buy immunology specialist Calypso Biotech BV for $425 million. 💉 Acquisition includes potential autoimmune treatment CALY-002. 🧪 Exciting developments in celiac disease and eosinophilic esophagitis research.
Shocking FDA Investigation: Obesity Drugs Linked to Suicidal Thoughts
📢 FDA investigates suicide risk of obesity drugs semaglutide and tirzepatide, as well as hair loss and aspiration during surgery. Novo Nordisk and Eli Lilly cooperate.
